(25 Jun 2024, 12:12)

USFDA classifies inspection of Cipla's Patalganga unit as 'Voluntary Action Indicated'

Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

Cipla announced that the United States Food and Drug Administration (USFDA) vide communication dated 25 June 2024 has classified the inspection of the company's manufacturing facility in Patalganga as Voluntary Action Indicated (VAI).

More News

(28-Aug-2024 09:06)
Shares of Orient Technologies list today
(28-Aug-2024 09:09)
PDS concludes QIP issue with fund raise of Rs 430 cr
(28-Aug-2024 09:12)
PDS allots 80.22 lakh equity shares under QIP issue
(28-Aug-2024 09:32)
Infibeam's first AI product 'AI Facility Manager' secures multiple contracts

More Company News View Company Information

Hot Pursuit (12-Aug-2024 13:00)
Cipla Ltd up for five straight sessions
Hot Pursuit (08-Aug-2024 13:05)
Cipla Ltd gains for third straight session
Corporate News (02-Aug-2024 18:26)
Cipla allots 6,815 equity shares under ESOS
Hot Pursuit (26-Jul-2024 15:53)
Cipla spurts as Q1 PAT rises 18% YoY to Rs 1,178 cr
Results - Announcements (26-Jul-2024 16:06)
Cipla consolidated net profit rises 18.27% in the June 2024 quarter
Corporate News (26-Jul-2024 20:06)
Cipla appoints senior management personnel
Corporate News (26-Jul-2024 20:07)
Board of Cipla appoints directors

Corporate News

USFDA classifies inspection of Cipla's Patalganga unit as 'Voluntary Action Indicated'